The sale of remaining rights to Allogene ends acrimony between the two companies.

Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.